New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
08:34 EDTCVMCEL-SCI reports 93% sequential enrollment increase in head and neck cancer trial
CEL-SCI announced that during the month of June the company enrolled 19 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine. A total of 54 patients were enrolled over the past three months, with 21 enrolled in April, 14 in May, and 19 in June. This marks a 93% increase over the prior three month period when a total of 28 patients were enrolled. So far, a total of 218 patients have been enrolled in the study. The study is expected to complete enrollment of 880 patients by the end of 2015. “As a result of active patient recruitment ongoing in an increasing number of clinical centers around the world, we are seeing the kind of acceleration we expect in patient enrollment numbers. With the United Kingdom having recently cleared our study, we are well past the halfway mark for country approvals. We are looking forward to receiving approvals from multiple additional countries later this year before being fully approved in all participating countries,” stated CEL-SCI CEO Geert Kersten.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
08:17 EDTCVMCEL-SCI reports enrolling 25 patients in February for Multikine study
CEL-SCI announced that in February it has enrolled 25 patients with advanced primary, not yet treated, head and neck cancer into its phase III head and neck cancer trial for its investigational immunotherapy Multikine -- Leukocyte Interleukin, Injection. A total of 377 patients have been enrolled in study in head and neck cancer as of February 28. “During the month of February we also received clearance in the Philippines, Malaysia and Belarus to begin patient enrollment in those countries. This is expected to result in an even higher number of patients being enrolled in the study in March,” stated CEL-SCI CEO Geert Kersten. The goal is to enroll a total of 880 patients through approximately 100 clinical centers in about 25 countries by the end of 2015.
March 2, 2015
08:46 EDTCVMCEL-SCI cleared to enroll patients in trial in Belarus
Subscribe for More Information
February 19, 2015
08:06 EDTCVMCEL-SCI says Malaysia approves patient enrollment for Phase 3 Multikine trial
CEL-SCI announced the Ministry of Health Malaysia has cleared the company to commence patient enrollment for its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine -- Leukocyte Interleukin, Injection -- in Malaysia. Malaysia is the 20th country to approve CEL-SCI’s Phase III trial, which now has over 350 patients enrolled. “Our plan called for having the trial cleared and conducted in a total of 21 countries, the United States plus 20 other countries. We are almost there,” stated CEO Geert Kersten. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use